ReviewCancer2011
Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer.
Review in Cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 52 citations in OpenAlex.
- Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion.Medical oncology (Northwood, London, England) · 2013Trial
- Long noncoding RNAs at the crossroads of smoking, oxidative stress, inflammation, and lung disease.Archives of toxicology · 2026Review
- An observational study of the impact of immediate breast reconstruction on perioperative inflammatory cytokines.Surgery today · 2023Observational
- Laboratory Parameters are Possible Prognostic Markers in Patients with Advanced-stage NSCLC Treated with Bevacizumab plus Chemotherapy.Journal of Cancer · 2021Article
- Pharmacogenomics, Pharmacokinetics and Circulating Proteins as Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review.Journal of personalized medicine · 2020Review
- Urinalysis by combination of the dipstick test and urine protein-creatinine ratio (UPCR) assessment can prevent unnecessary lenvatinib interruption in patients with thyroid cancer.International journal of clinical oncology · 2020Article
- Long non-coding RNAs: How to regulate the metastasis of non-small-cell lung cancer.Journal of cellular and molecular medicine · 2020Review
- Article
- PD-L1 Expression Is Associated With VEGFA and LADC Patients' Survival.Frontiers in oncology · 2019Article
- Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers.Cancer medicine · 2018Review
- Association between an elevated level of HMGB1 and non-small-cell lung cancer: a meta-analysis and literature review.OncoTargets and therapy · 2016Article
- Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy.ESMO open · 2016Article
- Reduced expression of sushi domain containing 2 is associated with progression of non-small cell lung cancer.Oncology letters · 2015Article
- Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung Cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2015Article
- Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors.Translational oncology · 2014Article
- Vasohibin-1 expression detected by immunohistochemistry correlates with prognosis in non-small cell lung cancer.Medical oncology (Northwood, London, England) · 2014Article
- Insulin-like growth factor binding protein-2 level is increased in blood of lung cancer patients and associated with poor survival.PloS one · 2013Article
- Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer.Clinica chimica acta; international journal of clinical chemistry · 2012Article
- Tyrosine kinase inhibitors in lung cancer.Hematology/oncology clinics of North America · 2012Review
- The study on newly developed McAb NJ001 specific to non-small cell lung cancer and its biological characteristics.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Currently, nonsmall-cell lung cancer (NSCLC) is the leading cause of cancer-related death in the United States. Angiogenesis, the formation of new vasculature, is a complex and tightly regulated process that promotes metastasis and disease progression in lung cancer and other malignancies. Developmental antiangiogenic agents have shown activity in NSCLC, and bevacizumab, an antiangiogenic monoclonal antibody, is approved for the treatment of patients with advanced disease. However, predictive biomarkers are needed to guide the administration of antiangiogenic agents. It is possible that angiogenic molecules could accurately predict patient response to targeted antiangiogenic therapies, which would allow individualized and perhaps more effective treatment. Angiogenic signaling molecules may also have value as prognostic indicators, which may be useful for the management of NSCLC. Here the author provides an overview of angiogenic molecules currently being investigated as prognostic biomarkers in NSCLC and discusses their potential to guide treatment choices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.